MedPath

HORIZON THERAPEUTICS IRELAND DAC

🇪🇸Spain
Ownership
Subsidiary
Employees
-
Market Cap
-
Website

Clinical Trials

38

Active:28
Completed:3

Trial Phases

4 Phases

Phase 1:27
Phase 2:5
Phase 3:1
+1 more phases

Drug Approvals

1

NMPA:1

Drug Approvals

Inebilizumab Injection

Product Name
昕越
Approval Number
国药准字SJ20220007
Approval Date
Mar 8, 2022
NMPA

Clinical Trials

Distribution across different clinical trial phases (34 trials with phase data)• Click on a phase to view related trials

Phase 1
27 (79.4%)
Phase 2
5 (14.7%)
Not Applicable
1 (2.9%)
Phase 3
1 (2.9%)

Study to Evaluate HZN-457 in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2022-10-04
Last Posted Date
2023-09-07
Lead Sponsor
Horizon Therapeutics Ireland DAC
Target Recruit Count
36
Registration Number
NCT05565768
Locations
🇳🇿

New Zealand Clinical Research, Christchurch, New Zealand

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.